TAG:
specialty laboratories
California Lab Regulators Are A Tough Bunch
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: By law, government regulators cannot comment publicly about the actions they take against the companies they regulate. That’s why the lab industry never learned that other public lab companies operating in California, following inspections by state authorities, were judged …
California Is Lab Industry’s Bellwether Again
By R. Lewis Dark | From the Volume IX No. 6 – April 22, 2002 Issue
IT’S NO COINCIDENCE THAT two recent lab industry developments are centered around lab companies in California. Repeatedly that state has proven to be a valuable bellwether of lab industry trends for the nation. On the lab regulatory front, state officials from the California Department of …
State, Federal Regulators Target Specialty Labs
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Specialty Laboratories, Inc. has earned the dubious honor of being the first-ever publicly-traded laboratory to have its CLIA-88 license revoked by federal regulators, terminating its right to payment for services covered by Medicare and Medicaid. The revocation is slated to …
“April 22, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
Careside, Inc.’s point-of-care instruments for routine chemistry and hematology are moving into the clinical marketplace. (See TDR, November 22, 1999.) Through January, the company, based in Culver City, California, had placed 73 units, with another 17 on order. Careside 
“March 11, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 4 – March 11, 2002 Issue
Down in Orlando, Florida, Cognescenti Health Institute, now opening a newly-constructed clinical laboratory, has selected LabDat, Inc. to provide browser-based lab test ordering and results reporting. In response to the anticipated changes caused by genomic and prot…
More Consolidation: Quest Acquires AML
By Robert Michel | From the Volume IX No. 3 – February 18, 2002 Issue
CEO SUMMARY: In December, American Medical Laboratories, Inc. (AML) was preparing a second attempt to raise capital through an initial public offering (IPO). But a tempting purchase offer by Quest Diagnostics Incorporated led to a decision by AML’s owners to sell the company. This trans…
“February 18, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 3 – February 18, 2002 Issue
Lab execs and pathologists should pay close attention to this fact: Internet use by Americans significantly increased again last year. The Commerce Department reported that. as of September, 143 million people in the U.S. were using the Internet. This is 54% of the population and rep…
2001’s Ten Big Stories Presage Future Direction
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
CEO SUMMARY: During 2001, few labs found themselves under intense pressure to change or react to dramatic events in the healthcare marketplace. Like 2000, this past year was marked by evolutionary progress, not revolutionary change. However, continuing signs indicate that consumers will p…
ProxyMed & Medscape Select Atlas LabWorksâ„¢
By Robert Michel | From the Volume VIII No. 16 – November 26, 2001 Issue
CEO SUMMARY: ProxyMed and MedScape just announced contracts with Atlas Development Corporation. Both companies will integrate Atlas LabWorksâ„¢ for electronic test ordering and results reporting into software products they sell to labs and physicians’ offices. Such collaborations again …
Roche, Digene, Centrex, Labtest.com, Specialty Labs, Tripath Imaging
By Robert Michel | From the Volume VIII No. #15 – November 5, 2001 Issue
ROCHE DIAGNOSTICS POSITIONED TO SERVE PUBLIC HEALTH LABS HEIGHTENED CONCERNS over bioterrorist attacks have accelerated plans within the public health lab sector to acquire state-of-the art diagnostic technology in DNA typing and enzyme immunoassay. Roche Diagnostics has in…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized